{
  "primary": "ATXN3",
  "interaction_type": "direct",
  "upstream_interactor": null,
  "mediator_chain": [],
  "depth": 1,
  "support_summary": "PIAS1 is an E3 SUMO ligase that promotes the SUMOylation of ATXN3, enhancing its stability by protecting it from proteasomal degradation.",
  "functions": [
    {
      "function": "SUMOylation-Mediated Protein Stabilization",
      "arrow": "activates",
      "cellular_process": "PIAS1 (Protein Inhibitor of Activated STAT 1) functions as an E3 SUMO ligase that directly interacts with ATXN3 and catalyzes its covalent modification with SUMO (Small Ubiquitin-like Modifier) proteins.",
      "effect_description": "The SUMOylation of ATXN3 by PIAS1, particularly at lysine 166 (K166), enhances the stability of both wild-type and polyQ-expanded ATXN3. This modification protects ATXN3 from ubiquitin-mediated degradation by the proteasome, thereby increasing its cellular half-life and protein levels.",
      "biological_consequence": [
        "PIAS1 binds to ATXN3 → PIAS1 acts as an E3 ligase, facilitating the conjugation of SUMO1/3 to ATXN3 at specific lysine residues (e.g., K166) → SUMOylated ATXN3 is shielded from the ubiquitin-proteasome system → Proteasomal degradation of ATXN3 is inhibited → Cellular accumulation of stabilized ATXN3 protein"
      ],
      "specific_effects": [
        "PIAS1 knockdown leads to a dose-dependent decrease in both wild-type and mutant ATXN3 protein levels, an effect reversible by proteasome inhibitors.",
        "SUMO-1 modification at lysine 166 (K166) of polyQ-expanded ATXN3 increases its stability and cytotoxicity.",
        "PIAS1 stabilizes ATXN3 protein by inhibiting its ubiquitin-mediated degradation and increasing SUMO-conjugated protein levels."
      ],
      "evidence": [
        {
          "paper_title": "PIAS1 S510G variant acts as a genetic modifier of spinocerebellar ataxia type 3 by selectively impairing mutant ataxin-3 proteostasis",
          "journal": "Neurobiology of Disease",
          "year": 2024,
          "relevant_quote": "Through in vitro biochemical analyses and in vivo assays, we demonstrate that PIAS1 stabilizes both wild-type and mutant ataxin-3 (ATXN3).",
          "pmid": "39293559"
        },
        {
          "paper_title": "SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity",
          "journal": "PLoS One",
          "year": 2013,
          "relevant_quote": "Here we identified that the major SUMO-1 binding site was located on lysine 166. SUMOylation did not influence the subcellular localization, ubiquitination or aggregates formation of mutant-type ataxin-3, but partially increased its stability and the cell apoptosis.",
          "pmid": "23382880"
        }
      ],
      "pmids": [
        "39293559",
        "23382880"
      ],
      "interaction_effect": "activates",
      "interaction_direction": "primary_to_main",
      "function_effect": "activation"
    }
  ],
  "arrow": "binds",
  "direction": "main_to_primary",
  "intent": "regulation",
  "arrows": {
    "main_to_primary": [
      "activates"
    ]
  },
  "is_valid": true,
  "mechanism_correction": null,
  "mechanism": "PIAS1 (Protein Inhibitor of Activated STAT 1) functions as an E3 SUMO ligase that directly interacts with ATXN3 and catalyzes its covalent modification with SUMO (Small Ubiquitin-like Modifier) proteins.",
  "effect": "The SUMOylation of ATXN3 by PIAS1, particularly at lysine 166 (K166), enhances the stability of both wild-type and polyQ-expanded ATXN3. This modification protects ATXN3 from ubiquitin-mediated degradation by the proteasome, thereby increasing its cellular half-life and protein levels.",
  "summary": "ATXN3 activates PIAS1 to modulate sumoylation-mediated protein stabilization, ultimately affecting cellular accumulation of stabilized atxn3 protein.",
  "evidence": [
    {
      "paper_title": "PIAS1 S510G variant acts as a genetic modifier of spinocerebellar ataxia type 3 by selectively impairing mutant ataxin-3 proteostasis",
      "journal": "Neurobiology of Disease",
      "year": 2024,
      "relevant_quote": "Through in vitro biochemical analyses and in vivo assays, we demonstrate that PIAS1 stabilizes both wild-type and mutant ataxin-3 (ATXN3)."
    },
    {
      "paper_title": "SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity",
      "journal": "PLoS One",
      "year": 2013,
      "relevant_quote": "Here we identified that the major SUMO-1 binding site was located on lysine 166. SUMOylation did not influence the subcellular localization, ubiquitination or aggregates formation of mutant-type ataxin-3, but partially increased its stability and the cell apoptosis."
    }
  ],
  "pathways": [
    {
      "name": "Post-Translational Modification Crosstalk",
      "canonical_name": "Post-Translational Modification Crosstalk",
      "ontology_id": null,
      "ontology_source": null,
      "confidence": 0.75
    }
  ],
  "interaction_effect": "binding",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 3
  },
  "_arrow_validated": true,
  "arrow_notation": "ATXN3 <--binds-- PIAS1:",
  "protein_a": "PIAS1",
  "protein_b": "ATXN3",
  "discovered_in_query": "ATXN3",
  "first_discovered": "2025-11-29T18:36:19.038789Z",
  "last_updated": "2025-11-29T18:36:19.038789Z"
}